Botulinum toxin market is assessed to value over US$ 8 billion by the end of 2026 and to grow at a CAGR of over 7% during the forecast period of 2019-2026.
Botulinum toxin is supremely an essential way of preventing damage and strengthening of dental hard tissues. Botulinum toxin type A (BOTOX) does not involve the entrance of devices in the body and is generally utilized as a functional mode of treatment of multiple healing symptoms. Botulinum toxin is a natural protein produced by the anaerobic bacterium, Clostridium botulinum. Botulinum is used for the treatment of strabismus and is desired in the cosmetic market. Growing research activities expanded the scope of botulinum for the treatment of neurological conditions like spasticity, dystonia, tremor, and others. Clinically botulinum is used for the treatment of strabismus and huge demand in cosmetic applications. Growing research activities expanded the scope of botulinum for the treatment of neurological conditions like spasticity, dystonia, tremor, and others. Along with this, recent research activities have concluded that botulinum is also used for autonomic disorders like hypersecretory disorders, detrusor sphincter, and others.
Easy and perennial acceptance of Botox products has fuelled the market of botulinum toxin. FDA's approval for Dysport to treat lower leg in children has fuelled the market. Also the FDA's approval for OnabotulinumtoxinA to be used as a treatment for interim improvement in the emergence of moderate to severe forehead lines blended with frontal muscle activities in adults has further expanded the market.
The growing demand of botulinum in disease management led to the robust growth of the market. The adding significance of botulinum in chemo-denervation has generated huge demand among the general population. Also, the growing importance of self-appearance and aesthetics in the middle of the general population has fuelled the growth of the market. High spending capacity and huge demand aesthetics among the general population of developed economies fuelled the growth of the global market. However, the expensive treatment of botulinum has restricted the growth of the market. Also, less knowledge of cosmetic products in regions like Latin America and Rest of the World has hindered the potential of the market. More preference for local products in such regions has restricted the growth of the market.
Developed economies like North America and Europe account for more 60% of the market share. The US dominated the North America market due to high penetration among the general population and the end-user segment. UK, Germany, France, and Italy dominated the European market. The Asia Pacific is the most opportunistic market space for market players due to the limited presence of manufacturers. It represented a fast-growing region during the forecast period. Latin America and Rest of World is a highly untapped market due to the limited presence of manufacturers.
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=184&page=requestsample
Botulinum Toxin Market Restraint
• Expensive treatment
• More preference for local products
• Less knowledge of cosmetic applications
Botulinum Toxin Market Segmentation
By Application
• Clinical Application
• Cosmetic Application
By End User
• Hospitals
• Cosmetic Centres
• Outpatient Centres
By Region
• North America
• Latin America
• Europe
• Asia and Pacific
• Rest of the World
Purchase a Copy of this Premium Research Report & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=184&page=askfordiscount
Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants
FutureWise Key Takeaways
• Growth Aspects
• SWOT Analysis
• Key Trends
• Key data-points affecting key growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global botulinum toxin market by application, by end user, by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market.
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financial and core competencies
Table of Contents
1.1. Introduction
1.1.1.1. Scope and Objective
1.1.1.2. Assumptions and Acronyms
1.1.1.3. Forecast Factors
1.1.1.4. Research Methodology
1.2. Executive Summary
1.2.1.1. Industry Cluster Analysis
1.2.1.2. Competition Matrix
1.2.1.3. Strategies Recommendations
1.3. Market Definition
1.3.1.1. Report Scope (Inclusions & Exclusions)
1.3.1.2. Market Segmentation
1.4. Global Botulinum Toxin A Market Overview
1.4.1.1. Global Botulinum Toxin Market Revenue (USD Mn)
1.5. Key Inclusions
1.5.1.1. Porter’s Five Force analysis
1.5.1.2. Market Dynamics
1.5.1.3. Industry Trends
1.5.1.4. Regulatory Guidelines
1.5.1.5. Opportunities in Botulinum Toxin
1.6. Competition Dynamics
1.6.1.1. Company Share Analysis (2018)
1.6.1.2. Top 10 Product Pricing by Region
1.7. Global Botulinum Toxin Market Revenue (USD Mn), 2018-2026 by Application
1.7.1.1. Key Market Findings
1.7.1.2. Long Term ROI Segments
1.7.1.3. Revenue Opportunity Influencing Factors
1.7.1.4. Market Revenue (USD Mn) Assessment and Forecast by Application, 2018-2026
1.7.1.4.1.1. Clinical Application
1.7.1.4.1.2. Cosmetic Application
1.8. Global Botulinum Toxin A Market Revenue (USD Mn), 2018-2026 by End User
1.8.1.1. Key Market Findings
1.8.1.2. Long Term ROI Segments
1.8.1.3. Revenue Opportunity Influencing Factors
1.8.1.4. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
1.8.1.4.1.1. Hospitals
1.8.1.4.1.2. Cosmetic Centres
1.8.1.4.1.3. Outpatient Centres
1.9. Global Botulinum Toxin Market Revenue (USD Mn), 2018-2026 by Region
1.9.1.1. Key Market Findings
1.9.1.2. Long Term ROI Segments
1.9.1.3. Revenue Opportunity Influencing Factors
1.9.1.4. Market Revenue (USD Mn) Assessment and Forecast by Region,2026
1.9.1.4.1.1. North America
1.9.1.4.1.2. Latin America
1.9.1.4.1.3. Europe
1.9.1.4.1.4. Asia Pacific
1.9.1.4.1.5. Rest of world
1.10. North America Botulinum Toxin A Market Revenue (US$ Mn), 2018-2026
1.10.1.1. Key Market Findings
1.10.1.2. Long Term ROI Segments
1.10.1.3. Revenue Opportunity Influencing Factors
1.10.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
1.10.1.4.1.1. US
1.10.1.4.1.2. Canada
1.10.1.5. Market Revenue (USD Mn) Assessment and Forecast by Application, 2018-2026
1.10.1.5.1.1. Clinical Application
1.10.1.5.1.2. Cosmetic Application
1.10.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
1.10.1.6.1.1. Hospitals
1.10.1.6.1.2. Cosmetic Centres
1.10.1.6.1.3. Outpatient Centres
1.11. Latin America Botulinum Toxin Market Revenue (US$ Mn), 2018-2026
1.11.1.1. Key Market Findings
1.11.1.2. Long Term ROI Segments
1.11.1.3. Revenue Opportunity Influencing Factors
1.11.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
1.11.1.4.1.1. Brazil
1.11.1.4.1.2. Mexico
1.11.1.4.1.3. Argentina
1.11.1.4.1.4. Rest of Latin America
1.11.1.5. Market Revenue (USD Mn) Assessment and Forecast by Application, 2018-2026
1.11.1.5.1.1. Clinical Application
1.11.1.5.1.2. Cosmetic Application
1.11.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
1.11.1.6.1.1. Hospitals
1.11.1.6.1.2. Cosmetic Centres
1.11.1.6.1.3. Outpatient Centres
1.12. Europe America Botulinum Toxin Market Revenue (US$ Mn), 2018-2026
1.12.1.1. Key Market Findings
1.12.1.2. Long Term ROI Segments
1.12.1.3. Revenue Opportunity Influencing Factors
1.12.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
1.12.1.4.1.1. Germany
1.12.1.4.1.2. France
1.12.1.4.1.3. Spain
1.12.1.4.1.4. UK
1.12.1.4.1.5. Russia
1.12.1.4.1.6. Poland
1.12.1.4.1.7. Rest of Europe
1.12.1.5. Market Revenue (USD Mn) Assessment and Forecast by Application, 2018-2026
1.12.1.5.1.1. Clinical Application
1.12.1.5.1.2. Cosmetic Application
1.12.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
1.12.1.6.1.1.1. Hospitals
1.12.1.6.1.1.2. Cosmetic Centres
1.12.1.6.1.1.3. Outpatient Centres
1.13. Asia Pacific America Botulinum Toxin Market Revenue (US$ Mn), 2018-2026
1.13.1.1. Key Market Findings
1.13.1.2. Long Term ROI Segments
1.13.1.3. Revenue Opportunity Influencing Factors
1.13.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
1.13.1.4.1.1. Emerging Asia
1.13.1.4.1.1.1.1. China
1.13.1.4.1.1.1.2. India
1.13.1.4.1.1.1.3. ASEAN-5
1.13.1.4.1.1.1.4. Rest of Emerging Asia
1.13.1.4.1.2. Japan
1.13.1.5. Market Revenue (USD Mn) Assessment and Forecast by Application, 2018-2026
1.13.1.5.1.1. Clinical Application
1.13.1.5.1.2. Cosmetic Application
1.13.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
1.13.1.6.1.1. Hospitals
1.13.1.6.1.2. Cosmetic Centres
1.13.1.6.1.3. Outpatient Centres
1.14. Rest of World America Botulinum Toxin Market Revenue (US$ Mn), 2018-2026
1.14.1.1. Key Market Findings
1.14.1.2. Long Term ROI Segments
1.14.1.3. Revenue Opportunity Influencing Factors
1.14.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
1.14.1.4.1.1. Middle East
1.14.1.4.1.2. South Africa
1.14.1.4.1.3. North Africa
1.14.1.4.1.4. Rest of World
1.14.1.5. Market Revenue (USD Mn) Assessment and Forecast by Application, 2018-2026
1.14.1.5.1.1. Clinical Application
1.14.1.5.1.2. Cosmetic Application
1.14.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
1.14.1.6.1.1. Hospitals
1.14.1.6.1.2. Cosmetic Centres
1.14.1.6.1.3. Outpatient Centres
1.15. Company Profiles
1.15.1.1. Competition Landscape
1.15.1.2. Global Company Share (USD Mn) Overview, 2018
1.15.1.3. Company Profiles
1.15.1.3.1.1. Merz Pharma GmbH & Co. KGaA
1.15.1.3.1.1.1.1. Corporate Overview
1.15.1.3.1.1.1.2. Financial Performance
1.15.1.3.1.1.1.3. Peer Comparison & 3C marketing equation
1.15.1.3.1.1.1.4. Company Strategy & Channel Management
1.15.1.3.1.2. Allergan Plc
1.15.1.3.1.2.1.1. Corporate Overview
1.15.1.3.1.2.1.2. Financial Performance
1.15.1.3.1.2.1.3. Peer Comparison & 3C marketing equation
1.15.1.3.1.2.1.4. Company Strategy & Channel Management
1.15.1.3.1.3. Galderma
1.15.1.3.1.3.1.1. Corporate Overview
1.15.1.3.1.3.1.2. Financial Performance
1.15.1.3.1.3.1.3. Peer Comparison & 3C marketing equation
1.15.1.3.1.3.1.4. Company Strategy & Channel Management
1.15.1.3.1.4. Ipsen
1.15.1.3.1.4.1.1. Corporate Overview
1.15.1.3.1.4.1.2. Financial Performance
1.15.1.3.1.4.1.3. Peer Comparison & 3C marketing equation
1.15.1.3.1.4.1.4. Company Strategy & Channel Management
1.15.1.3.1.5. Pfizer Inc.
1.15.1.3.1.5.1.1. Corporate Overview
1.15.1.3.1.5.1.2. Financial Performance
1.15.1.3.1.5.1.3. Peer Comparison & 3C marketing equation
1.15.1.3.1.5.1.4. Company Strategy & Channel Management
1.16. Research Sources & Primary Verbatim
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com